Stockreport

ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial [Yahoo! Financ...

ImmunityBio, Inc.  (IBRX) 
PDF a tri-valent Adenovirus (Tri-Ad5) in combination with the company's IL-15 superagonist N-803 could potentially prevent colon and other cancers in individuals with Lynch [Read more]